Skip to main content

Table 3 Clinical response in 17 evaluable patients

From: Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

 

No. (%)

Clinical benefit

Median OS (months)

PR

1 (5.8)

7/17 (41%)

14

SD

6 (35.2)

PD

10 (58.8)

 

6.5

All 17 patients

  

10

  1. PR Partial response, SD Stable disease, PD Progressive disease, OS Overall survival.